Perioperative genitourinary infection associated with sodium-glucose co-transporter 2 inhibitor use
Context: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are a novel treatment approved for type 2 diabetes mellitus to lower hyperglycemia, systolic blood pressure, and promote weight loss. Commonly reported serious adverse events include increased mycotic urogenital infections, orthostatic hyp...
Main Authors: | Stephen Melnick, Priya Rajagopalan, Theresa Lynn, Anthony Donato |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2018-09-01
|
Series: | Journal of Community Hospital Internal Medicine Perspectives |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/20009666.2018.1527667 |
Similar Items
-
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
by: Sarayut Lahnwong, et al.
Published: (2018-07-01) -
Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature
by: Alexis Diaz-Ramos, et al.
Published: (2019-09-01) -
Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure
by: Alex Ali Sayour, et al.
Published: (2020-09-01) -
The analysis of a wide spectrum of activity of Sodium-Glucose co-transporter-2 inhibitors. A literature review
by: Magdalena Kozioł, et al.
Published: (2020-08-01) -
Sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors combination therapy in type 2 diabetes: A systematic review of current evidence
by: Awadhesh Kumar Singh, et al.
Published: (2016-01-01)